[{"orgOrder":0,"company":"SunWay Biotech","sponsor":"Gnosis by Lesaffre","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Small molecule","year":"2024","type":"Partnership","leadProduct":"Menaquinone-7","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"SunWay Biotech","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"SunWay Biotech \/ Gnosis by Lesaffre","highestDevelopmentStatusID":"12","companyTruncated":"SunWay Biotech \/ Gnosis by Lesaffre"}]

Find Clinical Drug Pipeline Developments & Deals by SunWay Biotech

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          euroPLX 86 Munich
                          Not Confirmed
                          euroPLX 86 Munich
                          Not Confirmed

                          Details : The partnership aims to launch SunWay's inaugural product, MenaQ7® Metabolic, featuring two key active ingredients, MenaQ7® Vitamin K2 as MK-7 and ANKASCIN® 568-R.

                          Brand Name : MenaQ7

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          March 14, 2024

                          Lead Product(s) : Menaquinone-7,Ankascin 568-R

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Approved

                          Sponsor : Gnosis by Lesaffre

                          Deal Size : Undisclosed

                          Deal Type : Partnership

                          blank